KRAS and neoplasm: Applying high doses of vitamin C in KRAS gene mutation‐driven tumours has resulted in progression in pre‐clinical studies of vitamin C. It was shown that vitamin C directs mitochondrial membrane and metabolic components and reduces the levels of adenosine triphosphate (ATP) and GLUT1, which can also make KRAS mutant cells vulnerable to chemotherapy agents.16